Self-management in Chronic Kidney Disease: An Ambispective Cohort Study

注册号:

Registration number:

ITMCTR1900002483

最近更新日期:

Date of Last Refreshed on:

2019-07-19

注册时间:

Date of Registration:

2019-07-19

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

慢性肾脏病自我管理双向队列研究

Public title:

Self-management in Chronic Kidney Disease: An Ambispective Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性肾脏病自我管理双向队列研究

Scientific title:

Self-management in Chronic Kidney Disease: An Ambispective Cohort Study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024633 ; ChiMCTR1900002483

申请注册联系人:

吴一帆

研究负责人:

刘旭生

Applicant:

Yifan Wu

Study leader:

Xusheng Liu

申请注册联系人电话:

Applicant telephone:

+86 13560324448

研究负责人电话:

Study leader's telephone:

+86 13503078703

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wuyifan007@gzucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

liuxu801@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国广东省广州市越秀区大德路111号广东省中医院

研究负责人通讯地址:

中国广东省广州市越秀区大德路111号广东省中医院

Applicant address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

Study leader's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Provincial Hospital of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

广东省中医院伦理委员会ZF2019-153-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/7/5 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广州市越秀区大德路111号广东省中医院研修楼1912室

Contact Address of the ethic committee:

Room 1912, Yanxiu Building, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Yuexiu District, Guangzhou, Guangzhou, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院肾病科

Primary sponsor:

Department of Kidney disease, Guangdong Province Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

广州市越秀区大德路111号广东省中医院研修楼8楼

Primary sponsor's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

中国广东省广州市越秀区大德路广东省中医院

Institution
hospital:

Guangdong Provincial Hospital of Chinese Medicine

Address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

慢性肾脏病

研究疾病代码:

Target disease:

Chronic Kidney Disease

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

其它

Others

研究目的:

观察自我管理对慢性肾脏病预后的影响。

Objectives of Study:

To observe the influence of self-management on prognosis of chronic kidney disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

年龄18-80岁; 符合CKD诊断标准; 签署了接受自我管理知情同意书并愿意分享临床资料者。

Inclusion criteria

1. Aged 18-80 years; 2. According to the diagnostic criteria for CKD; 3. Provided signed informed consent.

排除标准:

精神病或其他原因无法配合者; 已行替代治疗者。

Exclusion criteria:

1. Psychosis or unable cooperating with clinical staff for other reasons; 2. Had a history of alternative treatment.

研究实施时间:

Study execute time:

From 2019-08-01

To      2029-07-31

征募观察对象时间:

Recruiting time:

From 2019-08-01

To      2024-07-31

干预措施:

Interventions:

组别:

自我管理组

样本量:

500

Group:

Selfmanagement

Sample size:

干预措施:

自我管理

干预措施代码:

Intervention:

Self-management

Intervention code:

组别:

非自我管理组

样本量:

500

Group:

Non-selfmanagement

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

Conventional Treatment

Intervention code:

样本总量 Total sample size : 1000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三甲医院

Institution/hospital:

Guangdong Provincial Hospital of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

肾功4项

指标类型:

次要指标

Outcome:

Renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

次要指标

Outcome:

HbAlc

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功4项

指标类型:

次要指标

Outcome:

Liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床重大事件发生率

指标类型:

主要指标

Outcome:

Incidence of clinical events

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿蛋白肌酐2项

指标类型:

次要指标

Outcome:

Urine protein and creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量简表

指标类型:

次要指标

Outcome:

SF-12

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

次要指标

Outcome:

Urine routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

离子 5 项

指标类型:

次要指标

Outcome:

Ion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

FBG

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

碱性磷酸酶

指标类型:

次要指标

Outcome:

ALP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂 4 项

指标类型:

次要指标

Outcome:

Blood lipid

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

faeces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

无。

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

广东省中医院慢病管理系统

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

chronic disease management system of Guangdong Provincial Hospital of Chinese Medicine

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

我们采用电子采集和管理系统收集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic collection and management system are used to collect data.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above